中国血制品必将出现一个巨头

Ofweek维科网
Jun 30

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。中国血制品行业,正在发生一场大变局。从华润48亿元收购博雅生物,到海尔系125亿元控股上海莱士;从天坛生物13亿元吞并中原瑞德,再到近期中国生物拟46亿元拿下派林生物21.03%股份。短短五年间,中国头部血制品企业几乎都发生了资本异动,整个行业的竞争格局剧烈生变,正向深度整合时代演进。血液制品,作为国家重要的战略性储备物资及重大疾病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10